Twenty-six patients with low-grade lymphoma (LGL) (n ‫؍‬ 18) or chronic lymphocytic leukemia (CLL) (n ‫؍‬ 8) received allogeneic BMTs between 1985 and 1998. Median age was 42 years, median interval from diagnosis to transplant 22 months and median number of prior treatments three. Twenty (77%) had stage IV disease; 22 (85%) had never achieved CR. Donor source was HLA matched sibling (n ‫؍‬ 19, 73%), matched unrelated (n ‫؍‬ 6, 23%) or syngeneic (n ‫؍‬ 1). Conditioning therapy included total body irradiation in 23 patients and busulphan in three. Twenty-five received GVHD prophylaxis with cyclosporine A; ؉ methotrexate (n ‫؍‬ 19), ؉ methylprednisolone (n ‫؍‬ 2) or ؉ T cell depletion of allograft ؎ methotrexate (n ‫؍‬ 4). Sixteen patients are alive, a median of 2.4 years post BMT. Death occurred due to transplant complications (n ‫؍‬ 7) or underlying disease (n ‫؍‬ 3). Eighteen (12 LGL, six CLL) of 22 evaluable patients (82%) achieved CR post BMT. Cumulative incidence of refractory/recurrent disease was 18% (95% confidence interval (CI) 7-42%). Overall and event-free survivals were 58% (95% CI 35-75%) and 54% (95% CI 32-72%), respectively. Allogeneic BMT for young patients with advanced LGL or CLL is feasible and can result in long-term disease-free survival. Bone Marrow Transplantation (2000) 25, 605-612. Keywords: low-grade lymphoma; chronic lymphocytic leukemia; allogeneic bone marrow transplantation Low-grade lymphoma (LGL) and chronic lymphocytic leukemia (CLL) are indolent hematologic malignancies with median survival times approaching a decade.
Low-grade lymphoma (LGL) and chronic lymphocytic leukemia (CLL) are indolent hematologic malignancies with median survival times approaching a decade. [1] [2] [3] [4] [5] Although clinical remission can be achieved with standard [6] [7] [8] [9] and newer [10] [11] [12] [13] [14] therapies, prolonged freedom from recurrence has not been demonstrated for patients with advanced stage, making death from disease almost inevitable. 8, 9, 11, [13] [14] [15] [16] for younger patients, particularly those with refractory or recurrent disease, a more aggressive approach to treatment can be justified. [17] [18] [19] [20] High-dose therapy with allogeneic stem cell support is an attractive option for such patients, where marrow involvement is common and the occurrence of a graftversus-leukemia/lymphoma (GVL) effect [21] [22] [23] [24] [25] [26] may contribute to the achievement of long-term disease control. Worldwide experience with allogeneic transplantation in this setting is, however, still limited. We report results from 26 patients with LGL or CLL receiving allogeneic BMT at the Vancouver General Hospital since 1985.
Patients and methods

Patients
Twenty-six patients with LGL (n ϭ 18) or CLL (n ϭ 8) received allogeneic BMT between September 1985 and January 1998, during which time, a total of 589 allografts and 512 autografts were performed in adults by the Leukemia/BMT Program of British Columbia. Eligibility criteria included: (1) age р50-55 years (related donor) and р45-50 years (unrelated donor); (2) Karnofsky performance score (KPS) у80%; and (3) adequate pre-transplant organ function including left ventricular ejection fraction у40%, forced expiratory volume in 1 s у60% and diffusing capacity for carbon monoxide у50% of predicted, aspartate transaminase р4 times upper normal with no evidence of cirrhosis or active hepatitis and creatinine clearance у65 ml/min. Allogeneic BMT was considered for patients with refractory or recurrent disease. There were two exceptions: one patient with LGL and a disease duration of 3.7 years underwent syngeneic BMT as primary therapy; one patient with CLL and a white cell count of 870 ϫ 10 9 /l at presentation underwent BMT in first remission.
Individual patient characteristics are detailed in Table 1 . Median age was 42 years (range 20-52), 13 patients were male and 13 female. Histology in LGL patients included follicular small cleaved cell (n ϭ 12), follicular mixed (n ϭ 4), and small lymphocytic (n ϭ 2). Five of eight CLL patients had a B cell immunophenotype, two T cell, and one T cell prolymphocytic. Median interval from diagnosis to BMT was 22 months (range 4.4-154). Marrow involve-ment at diagnosis was present in 23 of 26 (88%). Prior therapy consisted of alkylating agents Ϯ prednisone in 14 patients (54%), nucleoside analogs Ϯ others in 11 (42%) and none in one patient. Number of lines of prior therapy was none (n ϭ 1), one (n ϭ 9), two (n ϭ 6), three (n ϭ 4), four (n ϭ 4), five (n ϭ 1) and six (n ϭ 1). Twenty-two patients (85%) had never achieved CR prior to BMT. Disease status at BMT was induction (n ϭ 1), induction failure (n ϭ 9), first CR (n ϭ 1), first PR (nϭ 1), first relapse (n ϭ 8), second CR (n ϭ 1), second PR (n ϭ 2), second relapse (n ϭ 2) and third PR (n ϭ 1). The highest disease stage (Rai or Ann Arbor as appropriate) reached prior to BMT was II in two patients, III in four patients, and IV in 20 patients. B symptoms were present at BMT in 11 of 18 (61%) of LGL patients. Pre-BMT KPS was 100% in 14 and 90% in 12 patients.
All patients provided written informed consent. Treatment protocols were approved by the institutional review board. Pre-BMT work-up included history, physical, complete blood count, biochemistry, bone marrow aspirate and biopsy and appropriate scans, chest X-ray, electrocardiogram, radionuclide ventriculogram, pulmonary function tests, creatinine clearance and others as indicated. Tissue biopsies were performed for staging or histologic purposes.
Conditioning regimens
Total body irradiation (TBI) containing conditioning regimens were utilized unless precluded by prior dose-limiting radiotherapy. The conditioning regimen consisted of TBI 1200 cGy in six fractions ϩ cyclophosphamide (CY) 50 mg/kg ϫ 3 in 12 patients, ϩ CY 60 mg/kg ϫ 2 in four patients (one of whom also had pre-transplant para-aortic, pelvic and inguinal involved field radiotherapy 1800 cGy in eight fractions), ϩ CY 60 mg/kg ϫ 3 in one patient, ϩ etoposide 1.8 g/m 2 and CY 2 g/m 2 ϫ 3 in two patients, ϩ etoposide 1.8 g/m 2 and CY 50 mg/kg ϫ 3 in one patient, ϩ methylprednisolone 5 mg/kg ϫ 3 ϩ antithymocyte globulin (ATG) 30 mg/kg ϫ 3 ϩ thiotepa 150 mg/kg ϫ 2 ϩ CY 50 mg/kg ϫ 3 in two patients receiving T celldepleted (TCD) marrow from unrelated donors. One patient received single fraction TBI 750 cGy ϩ CY 50 mg/kg ϫ 3, one bulsulphan (BU) 1 mg/kg ϫ 12 ϩ CY 60 mg/kg ϫ 2 and single fraction total lymphoid irradiation 750 cGy, one BU 0.75 mg/kg ϫ 16 ϩ melphalan 100 mg/m 2 ϩ CY 90 mg/kg, and one BU 1 mg/kg ϫ 16 ϩ CY 60 mg/kg ϫ 2.
Donors
Donor marrow source was HLA-matched sibling in 19 (73%), matched unrelated in six (23%), and syngeneic in one patient. Transplant details are summarized in Table 1 . In all cases, marrow cells were harvested from the pelvis. Marrow manipulation included T cell depletion in four cases and red cell Ϯ plasma depletion as appropriate for ABO incompatibility. The median (range) nucleated cell count was 3.0 (0.43-6.0) ϫ 10 8 /kg.
GVHD prophylaxis and treatment
GVHD prophylaxis consisted of intravenous cyclosporine A (CsA) ϩ short-course methotrexate (MTX) (n ϭ 19), CsA ϩ methylprednisolone (n ϭ 2), and none (n ϭ 1) in the patient with a syngeneic donor. TCD of the allograft was employed for four patients; ϩ CsA in three, ϩ MTX in one. TCD with an anti-CD3 antibody was performed using immunomagnetic bead cell separation. 42 Three of six patients undergoing unrelated donor BMT received TCD marrow. One older patient received a TCD sibling donor BMT with subsequent T cell add-back as part of a protocol aimed at decreasing toxicity while promoting a GVL effect. First-line treatment of acute GVHD included high-dose corticosteroids, followed by XomaZyme, 43 BT 563, 44 and ATG 45 as indicated.
Supportive care
Patients were nursed in high-efficiency particulate air (HEPA)-filtered rooms and hospitalized until stable post engraftment. Indwelling central venous catheters (Hickman type) were employed. Irradiated blood products were administered to maintain hemoglobin Ͼ90 g/l, and platelets Ͼ20 ϫ 10 9 /l. Infection prophylaxis included acyclovir in HSV-seropositive patients and acyclovir (until December 1991) or ganciclovir (from January 1992) in CMV-seropositive patients and/or donors. CMV negative blood products were provided for patients where CMV serostatus was negative in the patient/donor pair. Antifungal prophylaxis included none, fluconazole or low-dose amphotericin according to sequential policies. Empiric broad-spectrum antibiotics and amphotericin were used as required. Low-dose heparin (100 units/kg/day) 46 was used for veno-occlusive disease prophylaxis starting in 1994. Total parenteral nutrition was used as indicated. Following absolute neutrophil count (ANC) recovery to day 100, patients were followed in a dedicated Leukemia/BMT Medical Daycare outpatient facility. Septrin or pentamidine were given as Pneumocystis carinii pneumonia (PCP) prophylaxis from engraftment to cessation of immunosuppressive therapy. Patients with chronic GVHD received PCP and antibiotic prophylaxis.
Assessment of regimen-related toxicity and GVHD
Regimen-related toxicity was evaluated in eight organ systems according to the Bearman criteria. 47 Acute GVHD was staged and graded according to the Seattle 48 and Minnesota 49 systems, and chronic GVHD with the Glucksberg criteria. 48 
Statistics
Survival analysis using the method of Kaplan and Meier 50 was employed to estimate overall and event-free survival (with death, relapse, or second BMT as events) and to calculate the actuarial probabilities of transplant-related mortality, acute and chronic GVHD, and relapse. Univariate analysis was performed to examine for factors associated with survival, transplant-related mortality, and relapse. 
Results
Outcome
Sixteen of 26 patients are currently alive (13 with no evaluable disease, one with disease and two too early to evaluate) with a median follow-up of 2.4 (range 0.1-6) years. Median KPS is 90% (range 75-100). Ten patients died, a median of 72.5 days (range 16-395) days post BMT. Cause of death was regimen-related toxicity in four (days ϩ16, ϩ24, ϩ28 and ϩ34), GVHD ϩ infection in two (days ϩ76 and ϩ203), progressive multifocal leukoencephalopathy in one (day ϩ395), and refractory/recurrent disease in three patients (days ϩ69, ϩ166 and ϩ326). The cumulative incidence of treatment-related mortality was 30% (95% confidence interval (CI) 14-56%) (Figure 1 ).
Regimen-related toxicity
Regimen-related toxicity was р grade II in all organ systems in 18 patients (69%), grade III in one or more systems in four (15%), and grade IV in one or more systems in four (15%). Patients sustaining grade IV regimen-related toxicity had received either extensive prior therapy or an augmented conditioning regimen, and included: UPN 78-pulmonary hemorrhage, four lines of prior treatment plus local radiotherapy with conditioning; UPN 637-gastrointestinal toxicity, CY/TBI ϩ etoposide conditioning; UPN 682-pulmonary hemorrhage, intensive multiagent chemotherapy plus mantle and whole abdominal radiotherapy as prior therapy; and UPN 1091-pulmonary hemorrhage, intensive multiagent chemotherapy as prior therapy. 
Engraftment
Graft-versus-host disease
The actuarial incidence of acute GVHD grades II-IV was 54% (95% CI 37-74%), and grade III-IV was 26% (95% CI 12-49%). Eleven patients had no acute GVHD, two had grade I, seven grade II, two grade III, and four grade IV. Acute GVHD onset was a median of 21 days (range 11-43) post BMT. Of the four patients with grade IV acute GVHD, two received CsA and methylprednisolone as GVHD prophylaxis for sibling donor BMT, one CsA ϩ TCD of allograft and one CsA and MTX for unrelated donor BMT. One patient (UPN 988) had no GVHD initially, subsequently received T cell add-back to generate GVL and died from GVHD and aspergillus pneumonia. Eleven patients received prior fludarabine: three had no acute GVHD, two sustained grade I, four grade II, and two (both with unrelated donor) grade IV. The cumulative incidence of chronic GVHD was 54% (95% CI 30-82%), with onset a median of 163 days (range 100-553) post BMT. Chronic GVHD developed in five of eight evaluable prior recipients of fludarabine.
Disease response
Fifteen of 16 patients currently alive have no evidence of disease. One patient (UPN 1225) had a recurrence of LGL on day ϩ182 and remains well. Of the 10 patients who died, seven had no evidence of disease at death, one (UPN 985) had evidence of persistent LGL day ϩ152 and died of transplant complications day ϩ166, one (UPN 1114) had persistent LGL throughout and died of GVHD complications day ϩ69 and one (UPN 1136) had persistent CLL after BMT and subsequent donor leukocyte infusion (day ϩ99), and died from disease day ϩ326. Eighteen (12 with LGL and six with CLL) of 22 evaluable patients (82%) achieved CR after BMT. Seven of nine patients who had disease resistant to induction therapy (induction failure) achieved CR after BMT. Two patients (UPN 682, day ϩ34; UPN 1091, day ϩ24) died early without autopsy and were not evaluable for assessment of disease response. Four patients (UPN 985, 1114, 1136, 1225) did not achieve CR after BMT. The cumulative incidence of refractory/recurrent disease was 18% (95% CI 7-42%) (Figure 2) . No recurrences occurred after the first year. Overall survival was 58% (95% CI 35-75%) and event-free survival was 54% (95% CI 32-72%) (Figure 3 ).
Discussion
Allogeneic BMT has been performed relatively infrequently for LGL and CLL despite the demonstrated potential for cure in other hematopoietic neoplasms. Barriers to allografting in these indolent disorders have included the relatively long median survival with conven- tional treatment and older age at diagnosis. However, for young patients with recurrent advanced stage LGL 2,17 and CLL, 5, 20, 52 median survivals are in the order of 4-5 years, not dissimilar to that of chronic phase CML, a disorder for which allogeneic BMT is a standard therapy. It also appears likely that a GVL effect, perhaps similar to that in CML, plays an important role in disease suppression for these patients. [21] [22] [23] [24] [25] [26] 53 Is disease eradication possible with allogeneic BMT for patients with LGL and CLL? We obtained a CR in 18 of 22 evaluable patients. Interestingly, even in patients with refractory disease, complete response and long-term disease-free survival without prohibitive toxicity have been noted in this and other reports. [22] [23] [24] [25] [26] [27] [29] [30] [31] [32] 38 This is in contrast to many other malignancies where induction failure may be considered a relative contraindication to high-dose therapy, due to both lack of response to BMT and regimenrelated toxicity. The high CR rate in this series is in accord with results of allografting LGL and CLL reported from both single centers and registries. Molecular CR has been documented [24] [25] [26] 29, 30, 34, 35, 37, 38, 41, 53, 54 and prolonged diseasefree survival in some patients suggests cure may be possible. All recurrences to date in our patients have been early, in keeping with other reports in which late recurrences have been rare. 33, 40 GVL effects may well be pivotal in producing and maintaining CR in these indolent disorders. An immunologic anti-tumor effect of the graft has been demonstrated for lymphoma, 21, 22, 32 and CLL. [23] [24] [25] [26] Several published cases have shown persistent disease post-allogeneic BMT responding coincidentally with development of active GVHD (acute or chronic), or after donor leukocyte infusion (DLI). [23] [24] [25] [26] In the present series, one case of refractory T cell CLL proved resistant to BMT and subsequent DLI, but CR was achieved in the remaining cases of B and T cell CLL. These patients had disease with adverse prognostic features including hyperleukocytosis (WBC 870 ϫ 10 9 /l) at diagnosis (UPN 570), T cell phenotype (UPN 1000) and T cell prolymphocytic leukemia (UPN 1227). The final case was refractory to all prior therapy, and demonstrated slow but eventual complete regression of lymphocytosis post BMT in association with the development of chronic GVHD. Similar delayed responses have been reported in CLL [23] [24] [25] [26] and multiple myeloma. 55 The same was not noted in patients with LGL; rather CR, if achieved, was documented by day 100 evaluation. This discussion has relevance to autografting 21, 22, 32, 37, 38, [56] [57] [58] [59] where there is no GVL effect and mature data from randomized trials will be required to assess the role of this approach for LGL and CLL.
Regimen-related toxicity (RRT) is an issue of importance in these patients for whom prior therapy often includes alkylating agents and/or nucleoside analogues. In this series, high-grade RRT was more prevalent in heavily pretreated patients and those who received an augmented conditioning regimen, but was otherwise acceptable. Although a variety of conditioning regimens has been utilized, the majority has been TBI-based. There is, however, limited but successful experience with chemotherapy only regimens in this and other series, 22, 26, 28, 29, 31, 33, 40 suggesting these may be a useful alternative where TBI is not feasible.
Immunosuppression/immune dysregulation is of particular concern with LGL and CLL, being intrinsic to the underlying diseases and therapy-related with prolonged T cell suppression post-nucleoside analogues. Although not seen in this series, unusual infections (for example, listeriosis) have been documented, 39 and the role of specific prophylactic regimens is under evaluation. 60 It has been suggested that patients may experience less severe GVHD in the setting of prior fludarabine exposure, 41 perhaps related to prolonged immune effects on allo-reactivity including T cell suppression. Our series is too small to draw firm conclusions regarding fludarabine and GVHD. Eleven patients had prior fludarabine, including four receiving marrow from unrelated donors. Of these patients, three, including one recipient of an unrelated donor BMT, had no acute GVHD, two sustained grade I, four grade II, and two, both post-unrelated donor transplant, grade IV acute GVHD. Chronic GVHD developed in five of eight evaluable prior recipients of fludarabine. Analysis of larger numbers of patients will be required to determine the effect of prior fludarabine on the development of GVHD.
This series of 26 patients with LGL or CLL indicates that allogeneic BMT is a feasible strategy following failure of conventional therapy and can produce durable complete remissions. Owing to the indolent nature of these disorders, further follow-up is necessary to demonstrate the extent of long-term disease-free survival. It is promising, however, that the incidence of refractory/recurrent disease has been low thus far (ෂ20%), and late events have yet to be witnessed. Further work is required to determine optimal pretransplant therapy and timing for allogeneic BMT, and to evaluate the role of innovative strategies such as non-mye-loablative conditioning regimens, 61 radioimmunotherapy, 62 and infusion of donor leukocytes. 25, 61 
